• Mashup Score: 21
    Artivion Follows Recommendation to Stop PROACT Xa Clinical Trial | Artivion, Inc. - 2 year(s) ago

    Study Was Evaluating the Use of Apixaban in Patients Treated with Mechanical Aortic Valves ATLANTA, Sept. 23, 2022 /PRNewswire/ — Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has stopped the PROACT Xa clinical trial, a prospective, randomized, trial designed to determine if patients with an On-X mechanical aortic…

    Source: Artivion Inc.
    Categories: Cardiologists, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of HanCardiomd
      HanCardiomd

      The #PROACT Xa trial has been halted prematurely after it was found that #Apixaban carried a greater risk of blood clots leading to stroke when compared with #warfarin in patients with the on-X mechanical #AV https://t.co/Wqbla1Hr6y @mmamas1973 @HeartOTXHeartMD @SchakrabartiEP https://t.co/a2DbWbMbYC